UV1 is administered with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant and has previously been investigated in clinical phase I trials involving metastatic hormone-sensitive prostate cancer (14) and malignant melanoma in which UV1 was given in combination with ipilimumab (NCT02275416). The gene discussed is CSF2; the disease is melanoma.